Code42 Software, Inc., the Insider Risk Management (IRM) leader, today announced that it has closed a transaction with Mill Point Capital to spin off its CrashPlan business. The new entity, to be known as CrashPlan Group (CPG), includes more than 100 employees, all CrashPlan solutions and CrashPlan customers. Code42 will use the proceeds of the transaction to accelerate the growth of the Code42 Incydr™ product and the Code42 Instructor™ microlearning solution, and further develop its team domestically and internationally.

amazee.io is the only ZeroOps application delivery hub built by developers to free them from cloud deployment, migrations, and operations work. The company was founded in 2017 to improve the developer experience by fully automating application and infrastructure operations and integration tasks for application builders.

(“Prove”), the leader in digital identity, announced today it has joined the Visa Ready for BNPL (Buy Now, Pay Later) program. Prove will enable Visa’s BNPL clients to streamline account opening and registrations while creating a seamless user experience through its Prove Pre-Fill onboarding solution. Powered by Prove’s Phone Identity Network (PIN), Prove’s Pre-Fill solution expedites the digital onboarding process by pre-populating a form with verified identity information tied to a phone number, while mitigating fraud.

(“Prove”), the leader in digital identity, today announced a new partnership with All Access NFT, which provides premium NFT collectibles, and changes the way people collect, invest, and redeem real-world rewards. All Access NFT leverages its partnerships throughout the sports world, allowing users to support their favorite athletes, collect sets for a once in a lifetime experience, and bridge the gap between blockchain and real-world utility. The innovative NFT company will be using Prove’s Trust Score, Verify, and Pre-Fill offerings to protect its users from fraud and make their customer experience faster and easier. In the larger digital asset landscape, Prove’s technology is used by 2 of the top 3 cryptocurrency exchanges today.

This week’s announcement by NBCUniversal sparks the beginning of an innovative, new—and extremely exciting—multi-currency measurement era. We are honored to have been chosen from more than 120 companies as NBCU’s certified streaming measurement partner. For the first time ever, the complex, fragmented world of streaming measurement is unified. It’s comprehensive, census-level, interoperable, continuously measured, and transparent. Advertisers will now understand the independent value of streaming audience and the incremental reach of streaming audiences through cross-platform currencies based on Conviva’s certified Continuous Measurement Analytics technology.

DailyPay, a leading technology platform, today announced it has secured a $300 million revolving credit facility from Barclays. The revolving credit facility will provide DailyPay access to significant capital to service its ever-growing roster of partners, which includes America’s leading employers.

Code42 today announced it is beginning 2022 with continued strong momentum in its Insider Risk Management business, growing Annual Recurring Revenue more than 125% in 2021. Code42 is arming organizations with the tools and education they need to make a fundamental shift in the ways company data is protected from theft and loss in today’s collaborative and remote work environment – this focus will continue to drive Code42’s growth in 2022.

Code42 today announced it is beginning 2022 with continued strong momentum in its Insider Risk Management business, growing Annual Recurring Revenue more than 125% in 2021. Code42 is arming organizations with the tools and education they need to make a fundamental shift in the ways company data is protected from theft and loss in today’s collaborative and remote work environment – this focus will continue to drive Code42’s growth in 2022.

When Docker announced it was selling Docker Enterprise in 2019, it was a big surprise to industry watchers. Perhaps an even bigger surprise was that the buyer was Mirantis, a company best known for commercializing the OpenStack project. After the sale, Docker pivoted to a developer-focused company and reported last week it had $50 million in ARR last year.

NEW YORK & MIAMI–(BUSINESS WIRE)–HealthCare.com, a leading data-driven insurtech platform, announced today the extension of its recent Series C equity round, which was led by Oaktree Capital Management, L.P. (“Oaktree”) as well as existing investors AXIS Capital, Second Alpha and Link Ventures. The additional $31.5M in Series C equity financing came from healthcare-focused private equity firm Hildred Capital Management (“Hildred”), bringing the total funding round to $211.5M.

Second Alpha Partners sponsor PlasmaSaves.org, an organization founded during COVID-19 to facilitate the collection of plasma to save lives, is thrilled to announce a $20,000 donation to God’s Love We Deliver.

Apis Growth Fund II, a private equity fund managed by Apis Partners LLP, a UK-based asset manager that supports growth stage financial services and financial infrastructure businesses, has invested US$50 million in Giift, the global leader in loyalty program management and development. Apis Growth Fund II was the sole investor in the Series C round.

“We are humbled to be acknowledged as a top leader by G2, a ranking from customers and users of our product, showcasing the value and power of Prove’s platform, innovation, and commitment as a leader in the digital identity space,” said Rodger Desai, Co-Founder and CEO of Prove. “Prove is on a mission to deliver digital trust, allowing businesses to garner the confidence to do more in the digital-first world that continues to evolve.

Genetics testing company 23andMe received Food and Drug Administration clearance for its prostate cancer risk test, the company announced today. It’s 23andMe’s third clearance for a cancer risk report — the company also has tests for genes that predict breast and colorectal cancer risk.

23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today announced the first participant has been dosed in a Phase 1 clinical trial evaluating 23ME-00610 for the treatment of advanced solid tumors.